Actively Recruiting
First In Human Study of CX-2051 in Advanced Solid Tumors
Led by CytomX Therapeutics · Updated on 2026-03-25
160
Participants Needed
5
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this first-in-human study, CTMX-2051-101, is to characterize the safety, tolerability, and antitumor activity of CX-2051 as a monotherapy and in combination with bevacizumab in adult participants with advanced solid tumors.
CONDITIONS
Official Title
First In Human Study of CX-2051 in Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Metastatic or locally advanced unresectable solid tumor that has progressed after standard therapy
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Measurable disease per RECIST v1.1
- Consent to fresh biopsy or if medically contraindicated, recent (within 6 months) archival tumor tissue
- Additional inclusion criteria may apply
You will not qualify if you...
- Recent history (within last 2 years) of localized cancers not related to the current cancer
- Known active central nervous system (CNS) involvement by malignancy
- Systemic anticancer treatment, radiotherapy, or investigational agents within 14 days prior to first study treatment
- Previous treatment with antibody-drug conjugates (ADCs) containing Topo-I inhibitor payload
- Major surgery requiring general anesthesia within 4 weeks prior to first study treatment
- Elevated baseline laboratory values
- Serious concurrent illness
- Pregnant or breastfeeding
- Additional exclusion criteria may apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
Sarah Cannon Research Institute at HealthONE
Denver, Colorado, United States, 80218
Actively Recruiting
2
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
3
Carolina BioOncology Institute, PLLC
Huntersville, North Carolina, United States, 28078
Actively Recruiting
4
Sarah Cannon Research Institute, LLC
Nashville, Tennessee, United States, 37203
Actively Recruiting
5
START San Antonio LLC
San Antonio, Texas, United States, 78229
Actively Recruiting
Research Team
K
Karen Deane
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here